Search

Author/Creator Bohlmann, Rolf

2. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. (16th October 2017)

Authors:
Lücking, Ulrich; Scholz, Arne; Lienau, Philip; Siemeister, Gerhard; Kosemund, Dirk; Bohlmann, Rolf; Briem, Hans; Terebesi, Ildiko; Meyer, Kirstin; Prelle, Katja; Denner, Karsten; Bömer, Ulf; Schäfer, Martina; Eis, Knut; Valencia, Ray; Ince, Stuart; von Nussbaum, Franz; Mumberg, Dominik; Ziegelbau...
Journal:
ChemMedChem
Issue:
Volume 12:Number 21(2017)
Page Start:
1776
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution properties. Issue 1 (1st January 2016)

Authors:
Hartung, Ingo V.; Hammer, Stefanie; Hitchcock, Marion; Neuhaus, Roland; Scholz, Arne; Siemeister, Gerhard; Bohlmann, Rolf; Hillig, Roman C.; Pühler, Florian
Journal:
Bioorganic & medicinal chemistry letters
Issue:
Volume 26:Issue 1(2016)
Page Start:
186
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗